Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NetworkNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (O
NetworkNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Patented Drug Delivery Platform Could Revolutionize Nicotine Delivery
Biotechnology company and drug delivery platform innovator Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) technology is patent protected for cannabidiol and all other nonpsychoactive cannabinoids. The company also currently has patents pending for THC, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine, other psychoactive cannabinoids and other molecules. An article discussing the company reads, “Lexaria Bioscience has 10 patents granted with over 50 patents pending. Four of the granted patents focus on the delivery of nicotine. The company is not partnering with the tobacco industry. However, Bunka informed that Lexaria is exploring the potential use of its DehydraTECH technology to help people stop smoking. . . . The company’s technology has been shown to deliver nicotine to the brain quicker than traditional delivery systems. The goal for Lexaria is to put nicotine into some type of oral form to eliminate the need for inhalation and help people curb their smoking habits. DehydraTECH studies in 2018 included two animal studies that delivered pioneering results highlighting the improvements of nicotine delivery to blood plasma and across the blood-brain barrier (http://nnw.fm/4RGjQ). ”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
What's Holding Lexaria Back?
The fact that Lexaria has only received a patent for DehydraTech with CBD and not with THC!
All LPs are going to want to provide products with both cannabinoids so the lack of a patent for THC negates the chances of a licensing deal. This is probably why ChargD+ is only available with CBD and not THC also.
This patent is pending, let's hope that it is awarded soon, this would be a real game changer!
https://www.cnn.com/2018/12/07/investing/altria-cronos-investment-marijuana/index.html
New York (CNN Business)Altria hopes pot is the key to help it grow beyond its stagnant cigarette business.
Tobacco giant Altria is investing $1.8 billion in Canadian cannabis company Cronos Group. That will give Altria a 45% stake in the company, with an option for Altria to increase its stake to 55% over the next five years.
Reports of an Altria-Cronos deal first surfaced earlier this week. The decision by Altria to go ahead with an investment in Cronos shows that Altria is serious about investing in marijuana as a new growth area as sales of traditional cigarettes slow.
Altria's stock has fallen nearly 25% this year and the company is expected to report revenue growth of only about 1% this year and in 2019.
"Investing in Cronos Group as our exclusive partner in the emerging global cannabis category represents an exciting new growth opportunity for Altria," said Howard Willard, Altria's CEO, in a statement.
Shares of Altria (MO) rose 2% in early trading Friday while Cronos (CRON) soared more than 30%.
"Altria is the ideal partner for Cronos Group, providing the resources and expertise we need to meaningfully accelerate our strategic growth," said Cronos CEO Mike Gorenstein in a statement.
Gorenstein added that Cronos will use the investment from Altria to expand its distribution and infrastructure around the world and also boost its investments in research and development for new brands and products.
Cronos and other cannabis stocks have been thrust into the spotlight in the past few months following the legalization of recreational marijuana in Canada in October, as well as legalized recreational and medical pot in several US states last month.
With Democrats winning control of the US House, Congress may finally pass the Farm Bill, which would make it legal to produce hemp and potentially open the door for more products containing cannabidiol, or CBD.
Many alcoholic beverage, tobacco and other consumer products companies may want to bet on cannabis.
Canadian marijuana company Canopy Growth (CGC) already has received a multibillion dollar investment from Corona owner Constellation Brands (STZ).
Coca-Cola (KO) was rumored to be considering an investment in Canadian cannabis company Aurora (ACB).
Coca-Cola CEO says company has no plans for cannabis drinks
Coca-Cola CEO says company has no plans for cannabis drinks
But Coke shot down the talk in October. CEO James Quincey said the company "doesn't have any plans at this stage" to enter the CBD market.
Coke's archrival Pepsi (PEP) hasn't completely ruled out a move into cannabis. Chief Financial Officer Hugh Johnston told analysts during its earnings call in October that "it's fair to say we look at everything" in response to a question about cannabis.
The Canadian subsidiary of Molson Coors (TAP) has a joint venture with The Hydropothecary Corporation to produce cannabis-infused drinks for the Canadian market. Lagunitas, a beer brand owned by Heineken (HEINY), is selling a cannabis-infused sparkling water brand in California.
Investors seem to be betting that more deals could be coming. Shares of Canopy, Aurora, Tilray (TLRY) and Aphria (APHA) all surged Friday morning.
Lexaria Warrant Exercises
(via TheNewswire)
Kelowna, British Columbia / TheNewswire / January 25, 2019 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces it has received funds from the exer cise of warrants.
Lexaria has received US$108,000from the exercise of 180,000 warrants at the exercise price of US$0.60 previously granted to third parties who are neither officers nor directors of the Company and has issued 180,000 common shares as a result. Lexaria has also issued 100,000 restricted common shares at an issue price of US$1.31 as required by a consulting agreement.
No commissions or placement fees have been paid related to the funds received from these warrants exercised. Proceeds will be used for general corporate purposes.
The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
About Lexaria
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has ten patents granted in the USA and in Australia and has filed over 50 patent applications worldwide across ten patent families. Lexaria's technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
www.lexariabioscience.com
For regular updates, connect with Lexaria on Twitterhttps://twitter.com/lexariacorp
and on Facebook https://www.facebook.com/lexariabioscience/
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp.
Alex Blanchard, Communications Manager
(778) 796-1897
Or
NetworkNewsWire (NNW)
www.NetworkNewsWire.com
BEER, Hill Street Beverages
Yesterday RBC bought 984,040 and another 532,600 today.
What's happening with our licensee? Will we find out next week?
Alex Blanchard
Ablanchard@lexariabioscience.com
https://www.medicalnewstoday.com/articles/244972.php
The big disadvantage nanotechnology has to Lexaria's tech is the high cost and concerns over safety.
"However, across the range, there exist considerable challenges, the greatest of which appear to be how to scale up production of materials and tools, and how to bring down costs and timescales.
But another challenge is how to quickly secure public confidence that this rapidly expanding technology is safe. And so far, it is not clear whether that is being done."
Our licensee Hill Street Beverages (BEER) is trying to bust a move this morning. Looks like a breakout from a reverse head and shoulders bottom!
Yeah, it all makes a lot of sense. Back in Oct. Hill Street (BEER) said they were in discussions with a major LP in regards to an equity financing which they said should take place before the month end. This never happened but this was at the time Altria stepped in to negotiate an equity investment in CRON, so CRON probably had to step away. But now, one can assume they have the blessing of their new masters at Altria.
The chairman of Altria is not returning my phone calls. LOL
Prediction
Cronos (cron) will do an equity financing with Hill Street Beverages, giving them at least a 49% interest and a DehydraTech license in Canada. Then in order to acquire the exclusive US rights to Lexaria's DehydraTECH for use with CBD/THC either Cronos or Altria will take an equity interest in Lexaria Hemp (45%) with the option to purchase 100% in the future based on value.
The meeting materials for Cronos Group Inc.'s special meeting of holders of common shares to be held on Feb. 21, 2019, including the management proxy circular dated Dec. 31, 2018, prepared in connection with the proposed $2.4-billion equity investment by Altria Group Inc.
Thanks for joining in. I for one will be interested in your opinion of Lexaria DehydraTECH once you have completed your DD. You might also try phoning Mr. John Docherty at Lexaria.
Go to the US patent office and search for Lexaria's patents. That will probably be your best explanation of their technology.
"...an exclusive basis in the United States and a non-exclusive basis elsewhere globally."
So Altria now controls a LP. Altria has their own vaporization tech that they can use for the delivery of cannabis but they lack a delivery technology for drinks and edibles. Let me think, who could help them out here? I know Lexaria Hemp!
"Lexaria Hemp Corp., a US company globally licensed to provide DehydraTECH to the rapidly growing hemp-based foods and supplements industries. Lexaria Hemp Corp. is currently involved in discussions with a number of companies regarding the utilization of its technology in CBD-from-hemp products for the Canadian and US markets following recent announcements of regulatory advancement in both countries. Discussions with companies in other global markets are also underway with reportable progress expected soon."
https://www.forbes.com/sites/greatspeculations/2018/12/26/cronos-group-benefits-from-the-altria-deal-in-multiple-ways/#2c2ded993648
And another 1 million shares traded in The Great White North!
Lexaria Nicotine LLC and a subsidiary of Altria Group, Inc. have entered into a definitive investment agreement.
- The Altria investment will fund research on regulatory compliant, oral forms of nicotine delivery.
- Altria has been granted exclusive DehydraTECH (TM) license rights to commercialize oral nicotine products in the United States.
- Lexaria Bioscience retains majority equity ownership of Lexaria Nicotine LLC.
Kelowna, British Columbia / TheNewswire / January 15, 2019 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) ( "Lexaria Bioscience"), a drug delivery platform innovator, is pleased to announce that its wholly-owned subsidiary Lexaria Nicotine LLC ("Lexaria Nicotine") and Altria Ventures Inc., an indirect wholly owned subsidiary of Altria Group, Inc. (NYSE:MO) ("Altria"), have executed definitive agreements to pursue innovation in oral, reduced risk nicotine consumer products using Lexaria's patented DehydraTECH (TM) technology. Lexaria's DehydraTECH(TM) technology enhances the performance of beneficial compounds in ingestible products across four categories: taste & smell, speed of action, bio-absorption and bioavailability.
Funding
Altria is funding a milestone-based research & development program ("R&D Program") in exchange for a minority equity interest in Lexaria Nicotine and certain DehydraTECH(TM) license rights. Altria will provide initial funding of US$1 million, with the option for additional funding of up to US$12 million through multiple phased private financings.
R&D Program
Lexaria Nicotine will execute a comprehensive series of clinical investigations of oral forms of nicotine delivery, utilizing Lexaria's patented DehydraTECH TM technology.
DehydraTECH (TM) License
Altria has been granted a license to use Lexaria Bioscience's patented DehydraTECH (TM) technology for oral nicotine delivery forms on an exclusive basis in the United States and a non-exclusive basis elsewhere globally. Altria will pay Lexaria Nicotine a royalty on revenue generated from the sale of nicotine products containing DehydraTECH(TM), until such time it may acquire 100% ownership in Lexaria Nicotine.
Additional Information
Altria will initially have the right to appoint one of the seven directors on Lexaria Nicotine's board of directors and, through the additional phased investments, may have the right to appoint up to three of the seven directors.
Altria has the option to acquire 100% ownership interest in Lexaria Nicotine commensurate with then-current fair market value. Lexaria Bioscience has not sold or optioned any of its own equity. As announced on October 10, 2018, Lexaria Bioscience has created a number of individual subsidiaries - including Lexaria Nicotine - in a structure whereby Lexaria Bioscience retains ownership of its patented DehydraTECH (TM) technology and licenses its use to multiple molecular classes, including nicotine.
Management Commentary
"Lexaria Bioscience is proud that, after careful selection, Altria has chosen to fund research into DehydraTECH(TM) technology and potentially commercialize this technology for oral nicotine," remarks Chris Bunka, CEO of Lexaria Bioscience. "This partnership will provide significant benefits to Lexaria Bioscience and its shareholders with a world-class R&D Program and regulatory compliance process. We believe Altria is the best corporate partner we could work with to truly make a difference in the lives of millions of consumers."
"Lexaria Bioscience has repeatedly demonstrated the powerful effects of its patented DehydraTECH (TM) technology for enhancing the palatability and speed of onset of orally-consumed bioactive substances such as nicotine," added John Docherty, President of Lexaria Bioscience. "Laboratory research to date on oral nicotine formulations has been quite encouraging. We are very excited to advance the clinical phases of our comprehensive R&D Program together with Altria with a view to full commercial product development."
Advisors
Borden Ladner Gervais LLP acted as independent legal counsel to Lexaria Bioscience and Lexaria Nicotine. Hunton Andrews Kurth LLP acted as independent legal counsel to Altria.
About Lexaria Bioscience
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and quicker onset of lipophilic active molecules. Lexaria has ten patents granted in the USA and in Australia and has filed over 50 patent applications worldwide across ten patent families. Lexaria's technology provides more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
www.lexariabioscience.com
Lexaria Nicotine LLC is a United States domiciled, majority-owned subsidiary of Lexaria Bioscience Corp., focused on reduced-risk nicotine solutions.
www.lexarianicotineco.com
For regular updates, connect with Lexaria on Twitter https://twitter.com/lexariacorp
and on Facebook https://www.facebook.com/lexariabioscience/
About Altria Group
Altria's wholly-owned subsidiaries include Philip Morris USA Inc. (PM USA), U.S. Smokeless Tobacco Company LLC (USSTC), John Middleton Co. (Middleton), Sherman Group Holdings, LLC and its subsidiaries (Nat Sherman), Ste. Michelle Wine Estates Ltd. (Ste. Michelle) and Philip Morris Capital Corporation (PMCC). Altria holds an equity investment in Anheuser-Busch InBev SA/NV (AB InBev).
The brand portfolios of Altria's tobacco operating companies include Marlboro (R) , Black & Mild (R) , Copenhagen (R) and Skoal (R) . Ste. Michelle produces and markets premium wines sold under various labels, including Chateau Ste. Michelle (R) , Columbia Crest (R) , 14 Hands (R) and Stag's Leap Wine Cellars (TM) , and it imports and markets Antinori (R) , Champagne Nicolas Feuillatte (TM) , Torres (R) and Villa Maria Estate (TM) products in the United States. Trademarks and service marks related to Altria referenced in this release are the property of Altria or its subsidiaries or are used with permission. More information about Altria is available at altria.com and on the Altria Investor app.
Take a closer look at Altria and its companies on altria.com.
Follow Altria on Twitter at @AltriaNews.
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp.
Alex Blanchard, Communications Manager
(778) 796-1897
Or
NetworkNewsWire (NNW)
www.NetworkNewsWire.com
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. Lexaria Bioscience makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements, including but not limited to: that the R&D Program will be successful or result in any regulator-approved products or that the contemplated royalties will generate material revenue. Such forward-looking statements are estimates reflecting Lexaria Bioscience's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by Lexaria Bioscience include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in Lexaria Bioscience's public announcements and filings. There is no assurance that existing capital is sufficient for Lexaria Bioscience's needs or that it will be able to raise additional capital. There is no assurance that Lexaria Bioscience will successfully complete any other contemplated or existing technology license agreements; or that results from any studies will be favorable or in any way support future business activities of any kind. Scientific R&D is often unpredictable and unanticipated results could emerge from any study and have a material impact as can any results that cannot be reproduced in subsequent testing. There is no assurance that any planned corporate activity, scientific study, R&D, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria Bioscience's postulated uses, benefits, or advantages for the patented and patented technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). DehydraTECH TM technology is not intended to diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Copyright (c) 2019 TheNewswire - All rights reserved.
© 2019 Canjex Publishing Ltd. All rights reserved.
What a joke, American Premium has a market cap of $1,248,000. This article was a paid article to try and lump American Premium in with the big legitimate players methinks.
This is interesting because Growpacker had originally signed a licensing deal with Lexaria, a deal that was ultimately canceled and now they've signed with someone else.
"American Premium Water Corporation, a company with one foot already in the growing CBD beverage market with its LALPINA Hydro CBD water, announced in October that it developed a formulation using its proprietary Hydro-Nano technology for THC. In December it announced they had entered into an agreement with Growpacker, a California based company that does infusion and fulfilment in the CBD and cannabis sector. Growpacker has a number of relationships with dispensaries in the state, and provides the distribution network for the Company to sell into the US’s largest marijuana market."
Breaking News: The Multi-Billion Dollar US and Canadian CBD-Infused Beverage Race is On: Tilray, Coca Cola, Molson Coors Brewing Co., Heineken and American Premium Water Corporation on Watch
2019-01-14 10:30 ET - News Release
NEW YORK, Jan. 14, 2019 (GLOBE NEWSWIRE) -- OTCMarketsinsider.com News Commentary
2019 is poised to be a pivotal year for the cannabis-infused-beverage market. Investors seeking to profit from the early growth of this new opportunity have plenty of options to choose from.
Canaccord’s Bobby Burleson and Jonathan DeCourcey claimed that infused beverages could be poised to outpace general demand for marijuana products by two fold, taking 20% of the existing market for cannabis edibles by 2022.
Canadian cannabis company Tilray entered a $100 million joint venture with beer brewer AB InBev to study cannabis-based beverages. The joint venture, in which both companies will invest $50 million, will study non-alcoholic beverages containing THC, the psychoactive chemical compound in marijuana, as well as CBD, the non-active chemical.
Heineken also launched a JV in California's, the world's biggest marijuana market. In June 2018, Heineken subsidiary Lagunitas announced a partnership with cannabis company AbsoluteXtracts to market cannabis-infused sparkling water products under the brand name Hi-Fi Hops. The products became available to consumers in July 2018. One version of Hi-Fi Hops contains 10 mg of THC, while the other contains 5 mg of THC and 5 mg of CBD.
Coca-Cola Co. said it’s eyeing to enter the CBD market, becoming the latest beverage company to tap into surging demand for marijuana products as traditional sales slow. Coca-Cola says it’s monitoring the nascent industry and is interested in drinks infused with CBD.
Last August, Molson Coors entered into a joint venture with HEXO, a Quebec-based marijuana cultivator, to produce cannabis-infused beverages for the Canadian market. Canada legalized marijuana for all adults on October 17, though products like beverages, edibles, and vaporizers won't be available until the fall of 2019.
The CEO of Molson Coors is bullish on cannabis-infused beverages. During the company's third-quarter earnings call, CEO Mark Hunter said the cannabis market could total $7 billion to $10 billion in Canada alone. Nonalcoholic cannabis-infused beverages could account for as much as $3 billion, or 30% of the total market.
Mark Hunter said Molson Coors, through the joint venture, was "well-placed" to take a meaningful share of that market when it opens up. "We decided as a business that we did not want to be a spectator as this new market opened up," Hunter said. "And we clearly wanted to be a participant."
American Premium Water Corporation, a company with one foot already in the growing CBD beverage market with its LALPINA Hydro CBD water, announced in October that it developed a formulation using its proprietary Hydro-Nano technology for THC. In December it announced they had entered into an agreement with Growpacker, a California based company that does infusion and fulfilment in the CBD and cannabis sector. Growpacker has a number of relationships with dispensaries in the state, and provides the distribution network for the Company to sell into the US’s largest marijuana market.
For commentary inquiries, please contact: info@otcinsider.com
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CG undertakes no obligation to update such statements.
You should not rely on the information presented; you should do independent research to form your own opinion and decision. Information contained in our disseminated emails does not constitute investment, legal or tax advice upon which you should rely. The purchase of high-risk securities may result in the loss of your entire investment. Advertisements received by you are not a solicitation or recommendation to buy securities of the advertised company. OTCI was not compensated by, (OTC: HEINY), (NASDAQ:TLRY), (NYSE: TAP), (OTC: HIPH) or any other company mentioned in this article.
Full Disclaimer: http://www.otcinsider.com/disclaimer/
For commentary inquiries, please contact: info@otcinsider.com
Biolog has licensed DehydraTECH from Lexaria and it seems Biolog is selling products made using LXRP's tech to WCVC.
DehydraTECH uses only GRAS (generally recognized as safe) ingredients
This is important, a number of companies claim to be able to dissolve oils in liquid, but what chemical are they using as the emulsifier? Maltodextrin is being used by at least one company, yuk!
Very Low Nicotine Content Cigarettes
Nobodys going to buy this crap! They want nicotine, hello. If this is all that's left on the market then Vapes and LXRP's product will be in high demand. It's like saying, " fine you can smoke weed recreationally but we're taking all the THC out of it.."
https://www.businesswire.com/news/home/20181227005331/en/
Wallstreet, you might want to type what you want to say in your native language and then use Google Translate to change it to English.
It's your mind they want!
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Increases
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Increases the Performance of Products for Third-Party Partners
- Changing the way cannabinoids and nicotine enter the blood stream
- Enhancing products worldwide, with patents issued and pending in more than 40 countries
- Providing a powerful new delivery method with a cost of less than a penny per serving to implement
Smoking is an efficient way to absorb cannabis and nicotine into the blood stream. However, it is also a health hazard that takes the lives of over six million people each year through smoking-related diseases.
What would it mean for the cannabis, nicotine and other medicinal industries if the dangers of lighting up were eliminated from the equation? What if a more effective way of delivering drugs was developed that reduced quantity and increased effectiveness without the negative side effects? One company, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), set out to answer these questions.
Lexaria’s revolutionary technology, DehydraTECH, changed the way that fat soluble, plant-derived molecules (such as cannabinoids and nicotine) enter the body.
The first challenge when creating edibles is taste and smell. Cannabinoids and nicotine can be bitter when taken orally. For this reason, edibles often contain high levels of sugar. DehydraTECH masks the taste and smell, eliminating the need for unhealthy sweeteners while making the product more desirable for the consumer.
Once past the mouth, these molecules do not fully survive the acidic nature of the stomach. Though the ideal location for absorption is in the small intestine, the stomach damages the molecules before they have a chance to arrive. DehydraTECH provides protection during stomach transit and can even bypasses first pass liver metabolism when desired. The truth is that the vast majority of substances orally consumed end up being filtered through the body as waste. With the addition of DehydraTECH, this changes! Bio absorption is increased by five to 10 times.
Four different wholly owned subsidiaries operate under Lexaria. Each is empowered with global exclusive licenses to use and out-license DehydraTECH to third party partners within their respective industries in more than 40 countries where the technology is patented or patent-pending. Partners are offered a competitive edge and protection against inferior methodologies and outdated technology. DehydraTECH is suitable for use in processed foods, beverages, capsules, oral sprays, topical applications and more. Though the company is doing extensive research and evaluating the potential use of its technology for nicotine delivery, it is not partnering with the tobacco industry.
Chemicals or intimidating complex ingredients that require disclosure on food labels are not required additions when using DehydraTECH. Instead the edible tech works with commons GRAS ingredients that can be organic and gluten- and dairy-free. It does all of this while still costing partners less than a penny per serving to implement, making DehydraTECH a win-win for the partner and consumer, who both gain from the improved performance of the enhanced product.
Lexaria believes that one day, using technologies like DehydraTECH, foods and beverages will be able to replace smoking as the most effective delivery mechanism. The work the company is doing with cannabinoids and nicotine is paving a path toward providing a powerful new delivery method of pain relievers, vitamins, supplements and more.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Instadose Pharma is owned by https://www.excellencehealthgroup.com/
Excellence not only sells bulk oils but also offers "Proprietary cannabis delivery systems to service both the medical and recreational markets including solubility and stability enhancement, modified release, and taste masking:"